Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

September 8, 2020September 8, 2020

New Software Tool Aids Early Diagnosis of Parkinson’s Disease Psychosis

News

PointClickCare has developed a new software tool to aid in the early diagnosis of Parkinson’s disease psychosis. The tool, developed in partnership with the American Society of Consultant Pharmacists (ASCP), is ... Read more

July 22, 2020July 24, 2020

FDA to Review Nuplazid as Treatment for Dementia-related Psychosis

News

The U.S. Food and Drug Administration (FDA) will review Acadia Pharmaceutical’s application asking that Nuplazid (pimavanserin) also be approved to treat hallucinations and delusions associated with various forms of dementia-related psychosis, ... Read more

July 17, 2020July 21, 2020

Phase 3 Trial Tests PhotoPharmics’ At-home Light Therapy to Ease Parkinson’s Symptoms

News

A new Phase 3 clinical trial will test PhotoPharmics‘ light-based, at-home therapy device — called Celeste — for Parkinson’s disease. The “Celeste Light for PD Trial” — a collaboration between ... Read more

July 10, 2020July 10, 2020

New Insight May Unveil Ways to Lessen Side Effects of Deep Brain Stimulation in Parkinson’s Patients

News

Distinct connections between nerve cells in the brain may explain why some Parkinson’s disease patients develop impulsivity and behavioral problems after deep brain stimulation (DBS) therapy, according to a ... Read more

July 9, 2020July 10, 2020

Deep Brain Stimulation Not Linked to Greater Risk of Dementia for Parkinson’s Patients, Study Concludes

News

Long-term deep brain stimulation (DBS) is cognitively safe and does not increase the risk for dementia in people with Parkinson’s disease, according to the results of a 10-year follow ... Read more

July 6, 2020July 6, 2020

Ongentys Approved in Japan as Levodopa Add-on Therapy for ‘Off’ Periods

News

Ongentys (opicapone) has been approved in Japan as an oral, add-on daily treatment for Parkinson’s disease patients experiencing off periods while on a levodopa/carbidopa regimen. This decision adds Japan to the list of countries ... Read more

July 6, 2020July 8, 2020

$2.2M Grant Awarded to University of Buffalo to Develop Strategy for Early Parkinson’s Diagnosis

News

The University at Buffalo has received a $2.2 million grant from the National Institute of Neurological Disorders and Stroke to develop a new method for diagnosing Parkinson’s disease before ... Read more

June 29, 2020June 29, 2020

Equfina, Known as Xadago in US, Approved in S. Korea as Levodopa Add-on

News

Equfina (safinamide) has been approved in South Korea as an add-on therapy to levodopa for Parkinson’s disease patients who experience “off” episodes, Eisai, which is marketing this medication in ... Read more

June 18, 2020June 18, 2020

Changes in Structure of Alpha-synuclein Seen to Make Protein Prone to Clumping

News

Structural changes within alpha-synuclein can make this protein more prone to clumping — a common feature of Parkinson’s — a research group found, a discovery that might lead to ways of ... Read more

June 9, 2020June 9, 2020

NeuroMotor Pen, Tool for Early Disease Diagnosis, Soon Widely Available

News

Manus Neurodynamica, a medical technology company, has raised £750,000 in a financing round to support the rollout of NeuroMotor Pen, a digital pen with a patented sensor technology to help ... Read more

Pin It on Pinterest